Abstract
Nanotechnology has given scientists new tools for the development of advanced materials for the detection and diagnosis of disease. Iron oxide nanoparticles (SPIONs) in particular have been extensively investigated as novel magnetic resonance imaging (MRI) contrast agents due to a combination of favorable superparamagnetic properties, biodegradability, and surface properties of easy modification for improved in vivo kinetics and multifunctionality. This review discusses the basics of MR imaging, the origin of SPION’s unique magnetic properties, recent developments in MRI acquisition methods for detection of SPIONs, synthesis and post-synthesis processes that improve SPION’s imaging characteristics, and an outlook on the translational potential of SPIONs.
Magnetic resonance imaging (MRI) has become one of the most widely used and powerful tools for non-invasive clinical diagnosis due to its high soft tissue contrast, spatial resolution, and penetration depth1. In addition, images are acquired without the use of ionizing radiation or radiotracers that would cause unwanted harmful side-effects. Considerable research in medical MR imaging is focused on the development of contrast agents that can provide better delineation between healthy and diseased tissue. Magnetic nanoparticles (MNPs) are a major class of nanoscale materials currently under extensive development for improved diagnosis of a wide range of diseases, including cancer2, cardiovascular disease3 and neurological disease4. The nanoscale dimensions of MNPs give rise to unique magnetic properties and the ability to function on a cellular and molecular level5. It is the combination of these characteristics that make MNPs such promising contrast agents in MRI applications.
Among the various MNPs under investigation, superparamagnetic iron oxide nanoparticles (SPIONs) have attracted considerable interest due to their excellent magnetic properties, biocompatibility6 and biodegradability7. While the in vivo applications of many nanoparticle-based contrast agents are hampered by toxicity concerns, SPIONs of several formulations have been approved by the Food and Drug Administration (FDA) as MRI contrast agents. These include Lumiren® for bowel imaging8, Feridex IV® for liver and spleen imaging9, and Combidex® for lymph node metastases imaging10. Recent advances in this field have further improved the magnetic and physiochemical properties of SPIONs11, broadening their potential clinical applications.
MR and relaxation properties of SPIONs
Principles of MRI contrast
MRI employs a strong magnetic field that aligns the magnetic moments of protons in a sample producing an equilibrium magnetization along the z-axis (Mz) with a magnitude of M0. A radio frequency (RF) pulse, at a resonance frequency capable of transferring energy to protons, rotates their magnetic moments off the z-axis in phase at an angle called the flip angle. The choice of flip angle depends on the imaging sequence applied but is generally to the transverse plane (xy-plane) causing a net magnetization of Mxy. Upon removal of the RF, the magnetic moments of protons relax to equilibrium1,12. The time required for the magnetic moments to relax to the equilibrium state, which is broadly termed the relaxation time, is tissue-dependent.
MRI contrast in soft tissue is due to differences in proton density, spin-lattice relaxation time (T1) and spin-spin relaxation time (T2) of protons. T1 is the time constant of the exponential recovery process of M0 along the z-axis after an RF pulse. Protons that relax rapidly (short T1) recover full magnetization along the z-axis and produce high signal intensities. For protons that relax more slowly (long T1), full magnetization is not recovered before subsequent RF pulses and inherently produce less signal and the so called saturation effect. T1 weighted images demonstrate anatomy well and are preferred when a clear image of structure is required12.
T2 is the time constant of the exponential decay of transverse magnetization (Mxy) after an RF pulse. T2 is related to the amount of time for precessing magnetic moments of protons to become randomly aligned in the xy-plane after an RF pulse, eventually resulting in a net magnetic moment of zero in the xy-plane. This dephasing process can be caused by a combination of local inhomogeneities in the magnetic field due to magnetic interactions of neighboring molecules and by macroscopic effects related to subtle variations in the external magnetic field. When the dephasing time accounts for both intrinsic molecular interactions and extrinsic magnetic field inhomogeneities it is termed T2*, and the produced images are considered to be T2* weighted. T2 weighted images are produced by eliminating the dephasing effects caused by extrinsic magnetic field inhomogeneities and account for molecular interactions alone. T2 weighted images produce good pathological information since collection of abnormal fluid appear bright against the normal tissue background1.
Spin-echo (SE) pulse sequences are used to eliminate external magnetic field effects and can generate T1 or T2 weighted images based purely on molecular interactions1. This signal eliminates extrinsic effects and provides quantitative T2 data for T2 weighted images. In its most basic form, the spin-echo scans employ two RF pulses with flip angles of 90° and 180° that produce a spin echo. The 180° pulse serves to refocus the transverse magnetization, cancelling dephasing effects caused by inhomogeneities in the local magnetic field. The time between the application of the 90° pulse and the peak of the echo signal is termed echo time (TE). Both TE and the time gap between RF pulse repetitions (TR) are responsible for the type of image produced. T1 weighted images are produced by selecting short TR (250–700 ms) and short TE (10–25 ms), while T2 weighted images are produced by long TR (>2,000 ms) and long TE (>60 ms)13.
In most tissue, intrinsic variation of T1 and T2 are small and often exogenous materials are employed clinically to enhance the contrast between the tissue of interest and the surrounding tissue. While nearly all MRI contrast agents affect both T1 and T2, usually the effects of contrast agents are more pronounced for either T1 or T2, leading to the categorization of these probes as T1 or T2 contrast agents. T1 contrast agents are used to increase signal intensity providing positive contrast enhancement in T1 weighted images, whereas, T2 contrast agents decrease signal intensity resulting in negative contrast enhancement in T2 weighted images. Currently the most widely used clinical contrast agents are based on paramagnetic chelates of lanthanide metals such as gadolinium14. The presence of paramagnetic ions near water protons shortens their T1 relaxation time through coordination with water molecules providing increased contrast. While gadolinium chelates are widely used, their short blood circulation times, poor detection sensitivity and toxicity concerns have led to the continued development of SPIONs for T2 contrast enhancement15,16.
Magnetic properties of SPIONs
The unique magnetic properties of SPIONs arise from a combination of atomic composition, crystal structure, and size effects. Bulk iron oxide consists of both Fe2+ and Fe3+ atoms and exhibits ferromagnetic behavior. Large ferrimagnetic crystals of Fe3O4 are comprised of multiple magnetic domains that exhibit magnetic moments that are aligned within a domain, but between domains, magnetic moments are oriented in random directions17. Ferrimagnetic particles below a critical diameter consist of a single magnetic domain. The critical diameter defined as the size at which domain boundaries are no longer energetically favorable, is highly dependent on the anisotropy of the particles, and varies for differing materials18-20. For spherical magnetite iron oxide (Fe3O4) the critical diameter is approximately 70–150 nm18,20,21. When the diameter of spherical magnetite particles is reduced below approximately 20 nm20, the thermal energy available at room temperature is greater than the magnetostatic energy well barrier. The magnetic dipole is free to fluctuate and as a consequence the particle acts like a paramagnetic Fe(2+,3+) atom. Since a nanoparticle comprises thousands of atoms it is described as superparamagnetic; it combines the high magnetization of bulk magnetite with the paramagnetic nature of Fe ions. (Fig. 1).
Effects of SPIONs on MRI contrast
SPIONs act primarily to alter T2 values of water protons surrounding the particle. When SPIONs present in tissue are subject to an external magnetic field the large magnetic moments of the particles align to create large heterogeneous field gradients through which water protons diffuse. The dipolar coupling between the magnetic moments of water protons and the magnetic moments of particles cause efficient spin dephasing and T2 relaxation leading to a decrease in signal intensity22. The contrast provided by SPIONs in a T2 weighted image is termed negative contrast enhancement since areas with high concentrations of SPIONs appear dark on MR images.
While SPIONs provide efficient shortening of T2 and generate excellent contrast enhancement in tissue with longer T2 characteristics, signal loss due to the presence of SPIONs can make it difficult to distinguish contrast enhancement in low signal body regions23,24. Senpan et al have recently reported a T1 weighted colloidal cross-linked iron oxide nanoparticle comprised of oleate-coated magnetite particles within a cross-linked phospholipid nanoemulsion25. This formulation decreased T2 effects and allowed positive T1 weighted contrast detection at nanomolar concentrations. Additionally, ultrasmall superparamagnetic iron oxide (USPIO), i.e., SPIONs with core diameters less than 10 nm, are capable of producing positive contrast in T1 weighted images26,27 While positive T1 contrast is possible with USPIO, this benefit is at the expense of their T2 effects18,28.
Another approach that has recently been investigated is the addition of a gadolinium chelate on the polymer coating of SPIONs29. This dual contrast agent efficiently reduces both T1 and T2 relaxation times and achieves good contrast in mice for both T1 and T2 weighted images. This unique combination allows for the acquisition of both highly detailed T1 weighted anatomical images and pathologically relevant T2 weighted images with a single imaging nanoprobe. In addition, such a contrast probe could provide enhanced T1 weighted imaging of brain tumors. Common clinical gadolinium chelates such as gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA) cannot traverse the blood-brain barrier (BBB) without the use of invasive techniques30,31, limiting their application in brain tumor imaging. A significant advantage of SPIONs is their relatively large surface area which allows for efficient addition of biologically active moieties such as BBB-penetrating peptides for non-invasive brain tumor imaging. For example, Veiseh et al have shown that SPIONs labeled with chlorotoxin (CTX) peptide, a targeting agent with high affinity for tumors of neuroectodermal origin through binding of the membrane-bound matrix metalloproteinase 2 complex, can pass the BBB and successfully target brain tumors in a transgenic mouse model32,33,34,35. The exclusion of Gd-DTPA from the parenchymal region signifies that the BBB is not compromised before or after the administration of CTX labeled SPIONs (Fig. 2), and highlights one advantage of SPIONs over commonly used Gd-chelates.
MRI acquisition methods for improved SPION detection
The detectability of SPIONs in vivo can be improved through synthesis techniques that enrich their magnetic properties (further discussed under “Important SPION design parameters” below), and through enhanced MRI acquisition methods that improve SPION detection. Acquisition methods that achieve low detection limits will be essential as the next generation of SPIONs moves toward clinical application. Lower detection limits will allow for administration of lower SPION dosages while improving contrast. In addition to methods that improve the negative contrast enhancement inherent to traditional T2 weighted methods, new techniques that generate positive contrast enhancement are currently being developed.
Historically, MRI acquisition methods for detection of SPIONs have been based on T2 weighted SE pulse sequences and T2* weighted gradient echo (GRE) pulse sequences that give quantitative and qualitative information about the location of SPIONs in vivo, respectively36-38. Recently, an effort to improve detection limits has led to the modification of traditional SPION pulse sequences37, as well as the application of nontraditional SPION pulse sequences such as fluid attenuated inversion-recovery (FLAIR)39,40.
The sensitivity of MRI in the detection of single SPION loaded cells increases linearly with increasing resolution and increases hyperbolically with increasing signal-to-noise ratios (SNR)37. Based on this observation, imaging with both high resolution and high SNR would give the greatest SPION detection capabilities; however, increasing resolution and SNR, both of which increase image acquisition time, would result in unreasonably long acquisition times. Since there are diminishing returns in increasing SNR, reduction in voxel size should be of primary concern to maintain acceptable imaging times. With this in mind, Hyen et al used a fast imaging employing steady-state acquisition (FIESTA) sequence based on a GRE pulse sequence that was able to detect femtomole quantities of SPIONs in labeled single cells in vitro37. With this pulse sequence images are weighted by a ratio of T2 and T1, and detection limits are comparable to those of positron emission tomography (PET)41.
The fluid-attenuated inversion recovery (FLAIR) sequence was developed to nullify signals from fluid and have shown to be useful in the diagnosis of central nervous system diseases42. This sequence first inverts the magnetic moments of protons in the z-axis before an additional 90° RF pulse at time TI (time between 180° and 90° RF pulse) tilts the magnetic moments into the xy-axis. This process can attenuate both tissue and/or fluid based on the chosen TI, but suffers from long imaging times. Fukukura et al recently demonstrated the effectiveness of a more rapid FLAIR echo-planar imaging (FLAIR EPI) sequence39,40 for the detection of malignant liver lesions with SPION contrast enhancement42. By suppressing signal from cysts, vascular structures and periportal tissue, the FLAIR EPI sequence was more sensitive for detecting malignant liver tumors than either the T2 weighted SE pulse sequences or the T2* weighted GRE pulse sequences in human patients.
Limitations of T2 contrast in low signal tissues have led to the development of specific pulse sequences that produce positive contrast in the presence of SPIONs. These methods attenuate background signal so that only fluid and tissue immediately adjacent to SPIONs are visible in MR images (Fig. 3). The current positive contrast sequences are classified as selective RF pulse methods43-45, dephased methods46, and off-resonance methods47. Selective RF pulse methods, such as inversion-recovery with on-resonant water suppression (IRON), employ inversion of magnetization in conjunction with a spectrally-selective on-resonant saturation prepulse that only generates signal from off-resonant protons in close proximity to SPIONs. Dephased methods employ a slice gradient in the region near the SPION that dephase background signal protons, but conserve signal from protons surrounding the SPION due to their induced magnetic field. Off-resonance methods utilize spectrally selective RF pulses that excite and refocus the off-resonance water surrounding SPIONs, while suppressing on-resonance signal from surrounding tissue. In addition to positive contrast sequences, post-processing methods that do not require special sequences for acquisition of positive contrast images have been developed48,49. Liu et al compared a post-processing susceptibility-gradient mapping (SGM) technique to IRON and the White Marker (dephased method) positive contrast sequences50. SGM more clearly delineates glioma tumors labeled with SPIONs than either the IRON or White Marker sequences in rats. Nevertheless, further studies are needed to compare the detection limit of the various positive contrast methods with those of the traditional spin echo methods.
Important SPION design parameters
The magnetic properties of the SPION are affected by the crystallinity and size of the magnetite core. In addition, surface modifications including polymer coatings and tissue targeting agents can have a profound effect on the efficiency of SPIONs as MRI contrast agents by increasing local concentrations of SPIONs in the tissue of interest while decreasing the concentration in background tissue. The efficiency of these contrast agents to increase the rate of relaxation of surrounding protons can be expressed by relaxivity (r1, r2), which is defined as the slope of the plot 1/T1 or 1/T2 as a function of SPION concentration. By carefully considering parameters of core synthesis and post synthesis modifications, materials with superior relaxivity properties and in vivo kinetics can be produced.
Core considerations
Synthesis methods of SPIONs have a dramatic effect on their crystallinity. The two most common methods are co-precipitation51-53 and thermal decomposition54,55. Synthesis of SPIONs by co-precipitation of Fe2+ and Fe3+ in aqueous solutions has traditionally been the most utilized synthesis method56. This method typically results in a lack of well-defined nanocrystalline size, stoichiometry, and magnetism28,57. Furthermore, the production often yields both maghemite (Fe2O3) and magnetite. Magnetite is preferred of the two materials because of its superior magnetic properties58. Synthesis parameters of the co-precipitation method must be rigorously controlled so that nanocrystalline magnetite is the major product to maintain acceptable MR signal-enhancing effect. Thermal decomposition of iron organometallic compounds is a more recent approach that produces monocrystalline particles of stoichiometric magnetite59. The high temperatures of the thermal decomposition method allows for a higher rate of diffusion during the growth phase of the SPIONs resulting in improved magnetic properties that demonstrate high relaxivity.
The core size of SPIONs has significant effects on relaxivity properties. The thermal decomposition synthesis method produces SPIONs with highly controllable, monodisperse size distributions. Through minor modifications to synthesis parameters, SPIONs with mean diameters ranging from 4 nm to 20 nm can be produced with a narrow size distribution60. Fig. 4 illustrates the correlation between particle size and T2 relaxation due to changes in magnetic properties. As particle size is reduced there is a corresponding reduction in saturation magnetization which in turn reduces the T2 relaxation capabilities of SPIONs. This phenomenon is a result of increased surface-to-volume ratios due to decreased particle diameter. As particle size is reduced, the percentage of atoms found on the particle surface increases and the curvature of the particle surface considerably increases, resulting in significant surface effects. The atoms on the surface have a reduction in nearest neighbors resulting in unsatisfied bonds, as well as noncollinear spins, spin canting and spin-glass-like behavior. These effects can severely diminish the saturation magnetization of small SPIONs by reducing the number of atoms that contribute efficiently to the particle’s magnetic moment61.
Surface modifications
Surface coating
Passivation of the iron oxide core is necessary for successful application of SPIONs in vivo. The high surface-to-volume ratio of nanoparticles yields high surface energies and are prone to surface oxidation which can have a significant effect on the magnetic properties of SPIONs58,61,62. In addition to surface oxidation, high surface energies can lead to particle aggregation or clustering in physiological environments63. Modification approaches for surface passivation of SPION cores generally provide a reduction in surface energy as well as either steric or electrostatic repulsion. Upon intravenous injection, SPIONs are subjected to protein adsorption, or opsonization, in the first step toward clearance from the blood stream by the reticuloendothelial system (RES). Evading RES uptake increases the blood half-life of SPIONs which is crucial for many MRI applications, as increased blood-circulation time maximizes the odds of SPIONs reaching their target tissue. A common technique to avoid opsonization and eventual clearance by the RES is to utilize hydrophilic coatings64 such as poly(ethylene glycol) (PEG)65 and zwitterionic66 polymers that resist protein fouling.
Many materials and coating approaches have been utilized for modifying the surface of SPIONs. Polymers are the most widely used coating materials and can be classified as hydrophilic or amphiphilic, neutral or charged, and homopolymers or copolymers67,68. These polymers can be anchored on the iron oxide surface by hydrogen bonds, electrostatic forces or through pseudo-covalent bonding16. In general, the coating should provide the SPION with a hydrophilic exterior to increase water solubility and stability.
The choice of coating material can have a significant effect on the relaxivity of SPIONs. The coordination chemistry of the inner capping ligand(s) and the hydrophilicity of the coating layer are important factors on particle relaxivity62,69. Daou et al have shown that coupling of surface coatings with the core of the SPION by carboxylates led to spin canting and decreased net magnetization, yet this effect was not observed when coupling was performed with phosphonates62. Additionally, the use of hydrophilic molecules such as polyethylenimine (PEI) as capping ligands allow for greater hydration around the magnetic core and yield higher proton relaxivity than SPIONs capped with hydrophobic ligands such as oleic acid69.
Polymer chain length, which corresponds to coating thickness, also has significant effects on relaxivity. Computer simulations have shown the effect of coating thickness on relaxivity is determined by two competing factors: the physical exclusion of protons from the SPION’s magnetic field and the residence time for protons within the coating zone70. The structure of the coating layer determines which factor dominates. LeConte et al studied the effects of chain length on relaxivity for SPIONs with a bilayer coating70. In this system, the inner hydrophobic layer excludes water, while the outer hydrophilic PEG layer allows for water diffusion in the coating zone. Increasing PEG chain length led to a reduction in r2 values. Here it seems that the exclusion of water from the core by the inner hydrophobic layer more than offsets any effect by increasing the hydrophilic PEG layer thickness. Recent studies by Hu et al have shown that when water molecules are not excluded from regions close to the SPION core, r2 relaxivity is increased with increased chain length71. SPIONs with diameters of 3, 4, 5 and 6 nm were coated with a single polymer layer of either short chain diethylene glycol or long chain PEG. Modification with PEG leads to an increase from 29 to 47, 42 to 69, 48 to 86, and 61 to 119 mM−1s−1 for the four SPION diameters respectively. These differences can be attributed to a larger water-slow diffusion layer of PEG modified SPIONs. Measurements of water diffusion coefficients in solutions of PEG of varying molecular weights indicate that water moves more slowly in more highly concentrated PEG environments72. Protons in the slow water diffusion layer spend a longer period of time in close proximity to the magnetic field of the SPION core allowing for more efficient dephasing of the magnetic moments of neighboring protons.
Targeting agents
Contrast agents that specifically target tissue can increases SNR by increasing local SPION concentration, potentially allowing for earlier detection of disease tissue such as small solid tumors and metastatic cells. Early SPIONs relied on passive targeting through the enhanced permeation and retention (EPR) effect which is the primary route for passive targeting in solid tumors. The EPR effect aids in nanoparticle uptake by way of leaky vasculature which allows particles with a hydrodynamic size generally less than 100 nm in diameter to cross from the vasculature into the interstitium73,74. Poor lymphatic drainage then aids in the entrapment of the particle in the solid tumor.
Alternatively, active targeting strategies provide mechanisms for specific accumulation of contrast agents within diseased tissue or cells. These strategies are based on the targeting of unique molecular signatures of afflicted cells, such as over-expressed growth factors and nutrient receptors75. Many types of ligands have been investigated in the targeting of these markers including antibodies, peptides, small molecules and aptamers76. A recent study by Sun et al illustrates the ability of targeting ligands to improve MR signal in diseased tissue77. In this study, PEG coated SPIONs were modified with CTX. Fig. 5 shows MR images that demonstrate tumor-specific SPION accumulation in tumors of a 9L xenograft mouse model. In a similar approach, Fang et al modified SPIONs with either cyclic arginine-glycine-aspartic acid (RGD) which targets tumor endothelial cells, or CTX78,79. SPIONs modified with RGD (NP-RGD) or CTX (NP-CTX) show significant increases in r2 values in tumors post injection in a xenograft U87-MG tumor mouse model, while non-targeted control SPIONs do not.
Active targeting is not only important for improving tissue targeting specificity, but has also shown to improve the distribution of SPIONs within the targeted tissue. Improved distribution of SPIONs in vivo can be an important factor in maximizing relaxivity in tissue and cells. SPIONs tend to accumulate and even cluster in some specific tissue and/or cells, affecting their relaxation properties80,81. Transverse relaxivity first increases with increased cluster size followed by a marked decrease as cluster size continues to grow. Improved nanoparticle distribution in tissue due to active targeting has been demonstrated by several research groups82-84. In studies by Kievit et al, SPIONs were modified with both DNA for gene therapy and CTX (NP:DNA-CTX), with SPION/DNA as a non-targeted control (NP:DNA). Fig. 6 shows the reduction of SPION clustering in C6 tumors of a xenograft mouse model. The improved SPION distribution can act to minimize any reduction in relaxivity due to large cluster formation, leading to higher SNR and in turn, better delineation of tumor margins.
Multimodal imaging
SPIONs were developed specifically as an MR imaging contrast agent, yet advances in coating technologies have allowed for the addition of other functional imaging moieties including those for optical32,85,86 (e.g. fluorophores) and nuclear imaging83,87,88 (e.g. radionuclides). These multifunctional SPIONs can be designed to incorporate complementary imaging modalities that synergistically provide more accurate information in vivo. Each imaging modality has its advantages and limitations and no one modality can give a comprehensive snap shot of a biological system.
Fluorescent labeled SPIONs may serve as a platform for the next generation of multifunctional probes for multimodality imaging. They have been developed with the goal of providing optical contrast that will enable surgeons to intraoperatively distinguish cancer tissue from healthy tissue32,85. These nanoparticles provide fluorescence by addition of numerous chromophores on the polymeric coating. SPIONs labeled with the near-infrared dye, Cy5.5, and CTX have shown the ability to produce both MRI and fluorescent tumor contrast in the brain of medulloblastoma transgenic mice (Fig. 7)32. Kumar et al recently developed a SPION conjugated to Cy5.5 and myristoylated polyarginine peptides for translocation across the BBB79. This probe showed remarkable uptake by U87 human glioma cells in vitro and excellent delineation of stereotactically injected tumors in vivo by MRI. These advances in SPION design would allow for both preoperative MR imaging and intraoperative optical monitoring with a single imaging probe that could improve survival rates of brain tumor patients through better delineation of tumor boundaries.
PET/MRI multimodal imaging may offer significant advantages over either imaging modality alone. Several research groups have recently developed dual PET/MRI contrast probes that combine a SPION core with the radionuclide, Cu-64 chelated on the polymeric surface of the nanoparticle83,87,88. A combined PET/MRI contrast probe in an integrated system could obtain near perfect spatial registration of molecular/functional PET and anatomic/functional MRI89,90. This combination allows highly detailed anatomical MR images to be coregistered with PET images that currently have greater sensitivity to the location of contrast probes than clinical MRI87. While SPIONs with multimodal imaging capabilities have been developed, their full potential has yet to be realized due to a lack of integrated multimodal imaging instrumentation.
Conclusions and Outlook
SPIONs have been extensively studied as MRI contrast agents and several formulations have been approved for clinical use. However, their widespread utility has yet to be realized due to limitations of current detection limits and a lack of tissue specificity. Recent developments in both MRI acquisition methods and SPION synthesis and postsynthesis modifications have led to significant improvements in SPION detection sensitivity and in vivo biodistribution. Beyond modifications to current MRI acquisition methods that demonstrate greater SPION sensitivity in T2 weighted negative enhancement images, new acquisition methods are being developed that can provide positive contrast and potentially address current limitations of SPION contrast enhancement. These imaging techniques take advantage of the magnetic properties of SPIONs that are continually improving due to a better understanding of core synthesis parameters that affect both core crystallinity and size, as well as postsynthesis modifications that can have a dramatic effect on their magnetic properties and in vivo behavior. In addition, modifications of SPION surfaces with optical and nuclear imaging probes for multimodal imaging could improve diagnosis methods by combining the beneficial characteristics of each imaging modality.
Improvement of current detection limits is necessary for the successful translation of newly designed SPIONs to broad clinical application. Because of their magnetic properties and ease of functionalization, SPIONs have gained interest as theranostic agents capable of both providing diagnostic information and delivering therapeutics. In addition, the use of SPIONs for cell tracking in stem cell therapies has shown great promise. The potential of such applications in clinical settings is dependent on the development of highly sensitive imaging methods, as well as efficient contrast probes, and will only be realized with improvements to current detection limits.
Despite recent improvements to imaging methods that exploit the magnetic properties of SPIONs, there is still a need to improve detection of these probes in vivo. Additional research is needed to both optimize methods for synthesis of highly reproducible monocrystalline SPIONs and to gain a better understanding of the effects of polymeric coatings on magnetic properties. By addressing these issues researchers can usher in the next generation of SPIONs for MR imaging.
Acknowledgements
We acknowledge the support of the NIH Grants R01CA134213, R01EB006043, and T32CA138312.
References
- 1.Edelman RD, et al. MRI: Clinical Magnetic Resonance Imaging. 2 ed W. B. Saunders Company; Philadelphia, Pennsylvania: 1996. p. 1150. [Google Scholar]
- 2.Ferrari M. Nat Rev Cancer. 2005;5(3):161. doi: 10.1038/nrc1566. [DOI] [PubMed] [Google Scholar]
- 3.Wickline SA, et al. Journal of Magnetic Resonance Imaging. 2007;25(4):667. doi: 10.1002/jmri.20866. [DOI] [PubMed] [Google Scholar]
- 4.Corot C, et al. Invest. Radiol. 2004;39(10):619. doi: 10.1097/01.rli.0000135980.08491.33. [DOI] [PubMed] [Google Scholar]
- 5.Sun C, et al. Advanced Drug Delivery Reviews. 2008;60(11):1252. doi: 10.1016/j.addr.2008.03.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sun CR, et al. Acs Nano. 2010;4(4):2402. doi: 10.1021/nn100190v. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Weissleder R, et al. American Journal Of Roentgenology. 1989;152(1):167. doi: 10.2214/ajr.152.1.167. [DOI] [PubMed] [Google Scholar]
- 8.Wang Y-X, et al. European Radiology. 2001;11(11):2319. doi: 10.1007/s003300100908. [DOI] [PubMed] [Google Scholar]
- 9.Bonnemain B. J. Drug Target. 1998;6(3):167. doi: 10.3109/10611869808997890. [DOI] [PubMed] [Google Scholar]
- 10.Harisinghani MG, et al. New England Journal of Medicine. 2003;348(25):2491. doi: 10.1056/NEJMoa022749. [DOI] [PubMed] [Google Scholar]
- 11.Veiseh O, et al. Advanced Drug Delivery Reviews. 2010;62(3):284. doi: 10.1016/j.addr.2009.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Berry E, Bulpitt A. Fundamentals of MRI. CRC Press; Boca Raton: 2009. p. 298. [Google Scholar]
- 13.Westbrook C, Roth C, Talbot J. MRI in Practice. 3 ed Wiley-Blackwell; Hoboken, NJ: 2005. p. 424. [Google Scholar]
- 14.Na HB, et al. Advanced Materials. 2009;21(21):2133. [Google Scholar]
- 15.Clarkson RB. Contrast Agents I. Vol. 221. 2002. Blood-pool MRI contrast agents: Properties and characterization; p. 201. [Google Scholar]
- 16.Terreno E, et al. Chemical Reviews. 2010;110(5):3019. doi: 10.1021/cr100025t. [DOI] [PubMed] [Google Scholar]
- 17.Bedanta S, Kleemann W. Journal of Physics D: Applied Physics. 2009;42(1):013001. [Google Scholar]
- 18.Gossuin Y, et al. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2009;1(3):299. doi: 10.1002/wnan.36. [DOI] [PubMed] [Google Scholar]
- 19.Mathew DS, Juang R-S. Chemical Engineering Journal. 2007;129(1-3):51. [Google Scholar]
- 20.Krishnan K. IEEE Transactions on Magnetics. 2010;46(7):2523. doi: 10.1109/TMAG.2010.2046907. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Butler RF, Banerjee SK. Journal of Geophysical Research. 1975;80(29):4049. [Google Scholar]
- 22.Holz M. Magnetic Resonance in Chemistry. 1993;31(13):S154. [Google Scholar]
- 23.Lipinski MJ, et al. Journal of the American College of Cardiology. 2008;52(6):492. doi: 10.1016/j.jacc.2008.03.062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Branca RT, et al. Proceedings of the National Academy of Sciences. 2010;107(8):3693. doi: 10.1073/pnas.1000386107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Senpan A, et al. ACS Nano. 2009;3(12):3917. doi: 10.1021/nn900819y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Park JY, et al. nanotechnology. 2008;19(36):7. doi: 10.1088/0957-4484/19/36/365603. [DOI] [PubMed] [Google Scholar]
- 27.Di Marco M, Sadun C, Port M, Guilber I, Couveur P, Dubernet C. Interanational Journal of Nanomedicine. 2007;2(4):609. [PMC free article] [PubMed] [Google Scholar]
- 28.Jun Y.-w., et al. Journal of the American Chemical Society. 2005;127(16):5732. doi: 10.1021/ja0422155. [DOI] [PubMed] [Google Scholar]
- 29.Bae K, Kim BY, Lee Y, Hwang JY, Park HW, Park TG. Bioconjugate Chemistry. 2010;21:505. doi: 10.1021/bc900424u. [DOI] [PubMed] [Google Scholar]
- 30.Ding D, et al. J. Neuro-Oncol. 2010;98(1):1. [Google Scholar]
- 31.Ding D, et al. Neurol. Res. 2010;32(8):810. doi: 10.1179/174367509X12581069052090. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Veiseh O, et al. Cancer Research. 2009;69(15):6200. doi: 10.1158/0008-5472.CAN-09-1157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Sun C, et al. Nanomed. 2008;3(4):495. [Google Scholar]
- 34.Veiseh O, et al. biomaterials. 2010;31(31):8032. doi: 10.1016/j.biomaterials.2010.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Veiseh O, et al. biomaterials. 2009;30(4):649. doi: 10.1016/j.biomaterials.2008.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Moffat BA, Reddy G. Ramachandra, McConville P, Hall D, Chenevert TL, Kopelman RR, Philber M, Weissleder R, Rehemtulla A, Ross BD. Molecular Imaging. 2003;2(4):324. doi: 10.1162/15353500200303163. [DOI] [PubMed] [Google Scholar]
- 37.Heyn C, et al. Magnetic Resonance in Medicine. 2005;53(2):312. doi: 10.1002/mrm.20356. [DOI] [PubMed] [Google Scholar]
- 38.Cole AJ, et al. Biomaterials. 2010;32(8):2183. doi: 10.1016/j.biomaterials.2010.11.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Moteki T, Sekine T. Journal of Magnetic Resonance Imaging. 2004;19(1):82. doi: 10.1002/jmri.10430. [DOI] [PubMed] [Google Scholar]
- 40.Kumano S, et al. American Journal of Roentgenology. 2003;181(5):1335. doi: 10.2214/ajr.181.5.1811335. [DOI] [PubMed] [Google Scholar]
- 41.Phelps ME. J Nucl Med. 2000;41(4):661. [PubMed] [Google Scholar]
- 42.Fukukura Y, et al. Journal of Magnetic Resonance Imaging. 2010;31(3):607. doi: 10.1002/jmri.22098. [DOI] [PubMed] [Google Scholar]
- 43.Stuber M, et al. Magnetic Resonance in Medicine. 2007;58(5):1072. doi: 10.1002/mrm.21399. [DOI] [PubMed] [Google Scholar]
- 44.Korosoglou G, et al. Journal of the American College of Cardiology. 2008;52(6):483. doi: 10.1016/j.jacc.2008.03.063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Suzuki Y, et al. Magnetic Resonance in Medicine. 2008;60(6):1269. doi: 10.1002/mrm.21816. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Mani V, et al. Magnetic Resonance in Medicine. 2006;55(1):126. doi: 10.1002/mrm.20739. [DOI] [PubMed] [Google Scholar]
- 47.Cunningham CH, et al. Magnetic Resonance in Medicine. 2005;53(5):999. doi: 10.1002/mrm.20477. [DOI] [PubMed] [Google Scholar]
- 48.Posse S. Magnetic Resonance in Medicine. 1992;25(1):12. doi: 10.1002/mrm.1910250103. [DOI] [PubMed] [Google Scholar]
- 49.Reichenbach JR, et al. Jmri-Journal of Magnetic Resonance Imaging. 1997;7(2):266. doi: 10.1002/jmri.1880070203. [DOI] [PubMed] [Google Scholar]
- 50.Liu W, et al. NMR Biomed. 2008;21(3):242. doi: 10.1002/nbm.1187. [DOI] [PubMed] [Google Scholar]
- 51.Yoo MK, et al. J. Nanosci. Nanotechnol. 2008;8(10):5196. doi: 10.1166/jnn.2008.1118. [DOI] [PubMed] [Google Scholar]
- 52.Forge D, et al. J. Phys. Chem. C. 2008;112(49):19178. [Google Scholar]
- 53.Finotelli PV, et al. Braz. J. Chem. Eng. 2008;25(4):759. [Google Scholar]
- 54.Meledandri CJ, et al. Langmuir. 2008;24(24):14159. doi: 10.1021/la8018088. [DOI] [PubMed] [Google Scholar]
- 55.Maity D, et al. Funct. Mater. Lett. 2008;1(3):189. [Google Scholar]
- 56.Gupta AK, Gupta M. biomaterials. 2005;26(18):3995. doi: 10.1016/j.biomaterials.2004.10.012. [DOI] [PubMed] [Google Scholar]
- 57.Sjögren CE, et al. Magnetic Resonance Imaging. 1997;15(1):55. doi: 10.1016/s0730-725x(96)00335-9. [DOI] [PubMed] [Google Scholar]
- 58.Nedkov I, et al. Journal of Magnetism and Magnetic Materials. 2006;300(2):358. [Google Scholar]
- 59.Park J, et al. Nat. Mater. 2004;3(12):891. doi: 10.1038/nmat1251. [DOI] [PubMed] [Google Scholar]
- 60.Sun S, et al. Journal of the American Chemical Society. 2003;126(1):273. doi: 10.1021/ja0380852. [DOI] [PubMed] [Google Scholar]
- 61.Lu A-H, et al. Angewandte Chemie International Edition. 2007;46(8):1222. doi: 10.1002/anie.200602866. [DOI] [PubMed] [Google Scholar]
- 62.Daou TJ, et al. Chem. Mat. 2008;20(18):5869. [Google Scholar]
- 63.Zhang Y, et al. Biomed Microdevices. 2004;6(1):33. doi: 10.1023/b:bmmd.0000013363.77466.63. [DOI] [PubMed] [Google Scholar]
- 64.Berry CC, Curtis ASG. Journal of Physics D-Applied Physics. 2003;36(13):R198. [Google Scholar]
- 65.Otsuka H, et al. Advanced Drug Delivery Reviews. 2003;55(3):403. doi: 10.1016/s0169-409x(02)00226-0. [DOI] [PubMed] [Google Scholar]
- 66.Jia GW, et al. Langmuir. 2009;25(5):3196. doi: 10.1021/la803737c. [DOI] [PubMed] [Google Scholar]
- 67.Fang C, Zhang MQ. Journal of materials chemistry. 2009;19(35):6258. doi: 10.1039/b902182e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Fang C, et al. Small. 2009;5(14):1637. doi: 10.1002/smll.200801647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Duan H, et al. The Journal of Physical Chemistry C. 2008;112(22):8127. [Google Scholar]
- 70.LaConte LEW, et al. Journal of Magnetic Resonance Imaging. 2007;26(6):1634. doi: 10.1002/jmri.21194. [DOI] [PubMed] [Google Scholar]
- 71.Hu F, et al. Nanoscale. 2010;2(10):1884. doi: 10.1039/c0nr00173b. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Vergara A, et al. Physical Chemistry Chemical Physics. 1999;1(23):5377. [Google Scholar]
- 73.Longmire M, et al. Nanomedicine. 2008;3(5):703. doi: 10.2217/17435889.3.5.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Kievit FM, et al. Adv Funct Mater. 2009;19(14):2244. doi: 10.1002/adfm.200801844. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Sunderland CJ, et al. Drug Development Research. 2006;67(1):70. [Google Scholar]
- 76.Alexis F, et al. Urol Oncol. 2008;26(1):74. doi: 10.1016/j.urolonc.2007.03.017. [DOI] [PubMed] [Google Scholar]
- 77.Sun C, et al. Small. 2008;4(3):372. doi: 10.1002/smll.200700784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Fang C, et al. Nanomedicine. 2010;5(9):1357. doi: 10.2217/nnm.10.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Kumar M, et al. Magnetic Resonance in Medicine. 2010;63(3):617. doi: 10.1002/mrm.22216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Larsen B, Haag MA, Serkova NJ, Shroyer KR, Stoldt CR. nanotechnology. 2008;19:26. doi: 10.1088/0957-4484/19/26/265102. [DOI] [PubMed] [Google Scholar]
- 81.Roch A, et al. Journal of Magnetism and Magnetic Materials. 2005;293(1):532. [Google Scholar]
- 82.Kievit FM, et al. ACS Nano. 2010;4(8):4587. doi: 10.1021/nn1008512. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Bartlett DW, et al. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(39):15549. doi: 10.1073/pnas.0707461104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Choi CHJ, et al. Proceedings of the National Academy of Sciences. 2010;107(3):1235. doi: 10.1073/pnas.0914140107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Veiseh O, et al. Nano Lett. 2005;5(6):1003. doi: 10.1021/nl0502569. [DOI] [PubMed] [Google Scholar]
- 86.Lee MJE, et al. PLoS One. 2010;5(3):8. [Google Scholar]
- 87.Lee HY, et al. J. Nucl. Med. 2008;49(8):1371. doi: 10.2967/jnumed.108.051243. [DOI] [PubMed] [Google Scholar]
- 88.Xie J, et al. Biomaterials. 2010;31(11):3016. doi: 10.1016/j.biomaterials.2010.01.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Cizek J, et al. Neuroimage. 2004;22(1):434. doi: 10.1016/j.neuroimage.2004.01.016. [DOI] [PubMed] [Google Scholar]
- 90.Myers R. British Journal of Radiology. 2002;75:S31. doi: 10.1259/bjr.75.suppl_9.750031. [DOI] [PubMed] [Google Scholar]